anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Risk, prevalence, management, and outcomes in chronic kidney disease (CKD) are influenced by social and broader determinants of health. Consequently, there are wide-ranging kidney health inequities. As patients are key stakeholders, their perspectives on the care they receive and on health status are central in guiding health system improvement, particularly to reduce the impact of disadvantage. Patient-reported experience measures (PREMs) and patient-reported outcome measures (PROMs) are important self-report tools in quality improvement, acting to guide initatives aimed at enhancing access to timely and relevant support. However, the extent to which PREMs and PROMs address the reduction of kidney health inequities is unclear. The aim of this review is to summarize how PREMs and PROMs are designed and implemented, highlighting key dimensions that are integral to health equity-oriented quality improvement in kidney care. There are several problems yet to be overcome so that such tools do not unintentionally reproduce kidney health gaps. Inclusive generation of the scope of tools, transparent reporting on attributes of patients who engage, and embedding PREMs and PROMs within a framework of value-based quality improvement is fundamental to their impact as part of equitable health system transformation.
The accompanying non-local manifestations during a maximum of 20 minutes of pressure stimulation of the zones defined by the concept of Professor Vojta will be observed. We will also examine the possible correlation between the magnitude of the response to Vojta Reflex Locomotion (VRL) and the degree of stress and anxiety on the part of the study participants. Approximately 20-30 participants will take part in the research. Manual stimulation of defined zones will be performed by an experienced physiotherapist who has successfully completed a course in the Vojta method. A Trigno Wireless EMG System Delsys device will be used to measure electrical muscle activity. Kistler force plates and a pliance-x® sensing system pedobarography device will be used to measure changes in standing. The SP-10 Pocket Spirometer Gima and wireless ECG will be used to measure changes in breathing and circulation. In addition, the DASS-42 and POMS questionnaires will be used. The aim of the study is to clarify whether during manual pressure stimulation of the zones defined by the above concept there is a change in electrical muscle activity, specific activity of the autonomic nervous system and whether there is a different partial pressure distribution in standing after the stimulation. Last but not least, the aim of the study is also to determine a possible correlation between the response rate to VRL and the level of stress and anxiety on the part of the study participants. All probands will be familiarized with the experimental measurement procedure and will sign an informed consent form prior to the start of the experiment. Measurements will be taken in the kinesiology laboratory of Physiotherapy department.
Chemotherapy-naive patients will be offered to participate in a two arms study. Following consent, patients will be randomized to one of two arms. Patients in both arms will be provided by booklet and audio-cassette that specify lifestyle recommendations (diet, physical activity and breathing exercises). Patients in one of the study arms will be provided in addition with frozen wheatgrass juice (recommended daily dosage of 55-110 CC daily). Patients in both arms will be asked to fill in a daily patient's diary monitoring the practice of the lifestyle recommendations.

Baseline assessment will include the following questionnaires: ESAS, MYCAW, FACIT- Fatigue. Evaluation will include weekly ESAS and FACIT-Fatigue questionnaire and subsequent evaluation (including ESAS, MYCAW, FACIT- Fatigue questionnaires) following 3 and 4 chemotherapy cycles of treatment. Follow-up evaluation will be performed at the completion of chemotherapy.
An ultrasound probe for percutaneous insertion into an incision and related methods are disclosed herein, e.g., for imaging neural structures at a surgical site of a patient. An exemplary ultrasound probe can be a portable ultrasound probe configured to be passed percutaneously into an incision and can have an imaging region extending distally from a distal tip of the probe. In one embodiment the ultrasound probe can be a navigated portable ultrasound probe. The ultrasound probe can be connected to a computing station and configured to transmit images to the computing station for processing. In another embodiment, an ultrasound probe can be part of a network of sensors, including at least one external sensor, where the network of sensors is configured to transmit images to the computing station for processing. The computing station can process and display images to visualize and/or highlight neurological structures in an imaged region.
The present invention relates to a lactate powder, more particularly a lactate powder having a lactate content of at least 20 wt. % and a water content of less than 3.5 wt. %, said powder comprising calcium cations as well as sodium cations. According to the invention, a calcium lactate powder combining high stability with excellent water dissolution properties can be obtained even though anhydrous calcium lactate represents the bulk of the powder if the powder additionally contains a certain amount of sodium lactate. The inventors have found that the presence of sodium lactate greatly improves the dissolution behavior of the anhydrous calcium lactate while maintaining the storage stability of the powder. The present inventors also established that the dissolution behavior of the powder can be further improved by the addition of a fast-dissolving carbohydrate material.
In group 2, the patients received experimental intermittent pneumatic compression in addition to the standard complex decongestive therapy. The complex decongestive therapy procedure was the same as above, but additionally, 30 minutes of intermittent pneumatic compression was instituted using a pump (Pulse Press Multi 6 Pro; MJS Healthcare Ltd. UK) operating at 30-40 mmHg of pressure. All groups were given a total of 20 treatment sessions, including daily 5 times a week for 4 weeks.
There are claimed as novel compounds benzoxathiols of the formula <FORM:0823251/IV (a)/1> in which R1 is an aryl or aralkyl group, an acyl group, an aryloxy or aralkoxy group, an -O-acyl or -S- acyl group, a hydrosulphide or sulphonyl group or salt thereof; R2 is a carboxyl or carboxylic ester group, an alkoxy group, an alkyl group with from 1 to 6 carbon atoms, an acyl group, a nitro- or amino-group or a sulphonyl group or a salt thereof; X is oxygen, sulphur or an imino group.  There are also mentioned compounds of the above formula in which R1 is additionally hydrogen, hydroxyl, C1-5 alkyl, C1-5 alkoxy or acyl and R2 is addi tionally hydrogen, hydroxyl or halogen. They may be prepared by the following methods.  The appropriate substituted hydroxy or thiohydroxy benzene is rhodanized by the action of an alkali rhodanide in methanol, saturated with sodium bromide and treatment with bromine or by the action of copper sulphate and ammonium rhodanide in aqueous solution.  The rhodanide first formed is rearranged in the course of the reaction to a 2-imino-benzoxathiol.  The latter when treated with dilute acid gives rise to the corresponding 2-oxo-benzoxathiol.  The benzoxathiols may also be obtained by the action of phosgene on the corresponding o-hydroxy thiophenols in the presence of pyridine and an inert solvent.  Alternatively, benzoxathiol compounds themselves may be converted to benzoxathiol compounds of the above formul  by standard methods of which examples are given.ALSO:Compositions useful for shedding dead skin lamell  from the scalp and in other skin infections comprise as the active ingredient a substance of the formula <FORM:0823251/VI/1> where R1 is hydrogen, a hydroxyl group, an alkyl or alkoxy group having 1 to 5 carbon atoms, an aryl or aryloxy group, an aralkyl or aralkyloxy group, an acyl, -O-acyl, or -S-acyl group, a hydrosulphide group or a sulphonyl group or salt thereof: R2 is hydrogen, a hydroxyl group, a halogen atom, a carboxyl or esterified carboxyl group, an alkyl group of 1 to 6 carbon atoms, an acyl or alkyloxy group, a nitro group, an amino group or a sulphonyl group or salt thereof: X is a divalent atom or group. These compounds are in admixture with a suitable carrier which may be liquid or solid, or gel or gel-like.  If liquid it may contain perfumes, wetting or dispersing agents, e.g. neutral alkylaryl sulphonate, preservatives, deodorants and solid insoluble carriers. The compositions which may be in the form of solutions, based on water, ethyl alcohol, oleyl alcohol, glycerol, cetyl alcohol, octadecyl alcohol or sorbital; emulsions; hair washing preparations, or powders contain the active ingredient in the range of 1-5% by weight.  [For preparation of the active ingredients, see Group IV (b)].
FIELD: medicine. SUBSTANCE: amyl oxybenzene interacts with acetyl chloride, the process is carried out in the presence of aluminium chloride. Thus prepared 4-amyl oxyacetophenone is nitrated to 4-amyloxy-3-nitroacetophenone. The latter compound interacts with hydrazine hydrate to produce desired compound. Desired compound has essential formula CHNO, its melting point is 67.6 %. EFFECT: revealed compounds having antimutagene activity. 5 tbl
PURPOSE: Pituitary adenomas are the most common tumor of the pituitary gland and comprise nearly 15% of all intracranial masses. These tumors are stratified into functional or silent categories based on their pattern of hormone expression and secretion. Preliminary evidence supports differential clinical outcomes between some functional pituitary adenoma (FPA) subtypes and silent pituitary adenoma (SPA) subtypes.
METHODS: We collected and analyzed the medical records of all patients undergoing resection of SPAs or FPAs from a single high-volume neurosurgeon between 2007 and 2018 at Brigham and Women's Hospital. Descriptive statistics and the Mantel-Cox log-rank test were used to identify differences in outcomes between these cohorts, and multivariate logistic regression was used to identify predictors of radiographic recurrence for SPAs.
RESULTS: Our cohort included 88 SPAs and 200 FPAs. The majority of patients in both cohorts were female (48.9% of SPAs and 63.5% of FPAs). SPAs were larger in median diameter than FPAs (2.1 cm vs. 1.2 cm, p < 0.001). The most frequent subtypes of SPA were gonadotrophs (55.7%) and corticotrophs (30.7%). Gross total resection (GTR) was achieved in 70.1% of SPA resections and 86.0% of FPA resections (p < 0.001). SPAs had a higher likelihood of recurring (hazard ratio [HR] 3.2, 95% confidence interval [95%CI] 1.6-7.2) and a higher likelihood of requiring retreatment for recurrence (HR 2.5; 95%CI 1.0-6.1). Subset analyses revealed that recurrence and retreatment were more both likely for subtotally resected SPAs than subtotally resected FPAs, but this pattern was not observed in SPAs and FPAs after GTR. Among SPAs, recurrence was associated with STR (odds ratio [OR] 9.3; 95%CI 1.4-64.0) and younger age (OR 0.92 per year; 95%CI 0.88-0.98) in multivariable analysis. Of SPAs that recurred, 12 of 19 (63.2%) were retreated with repeat surgery (n = 11) or radiosurgery (n = 1), while the remainder were observed (n = 7).There were similar rates of recurrence across different SPA subtypes.
CONCLUSION: Patients undergoing resection of SPAs should be closely monitored for disease recurrence through more frequent clinical follow-up and diagnostic imaging than other adenomas, particularly among patients with STR and younger patients. Several patients can be observed after radiographic recurrence, and the decision to retreat should be individualized. Longitudinal clinical follow-up of SPAs, including an assessment of symptoms, endocrine function, and imaging remains critical.
Patients receive fludarabine phosphate IV over 1 hour on days -8 to -6 and cyclophosphamide IV on days -7 and -6. Patients undergo TBI twice daily on days -4 to -1. Patients undergo unmanipulated single- or double-unit umbilical cord blood transplantation on day 0 and receive ex vivo-expanded cord blood progenitor cells IV over 4 hours following the last unmanipulated cord blood infusion. Patients initially receive CSP IV over 1 hour beginning on day -3. CSP may be given PO when the patient can tolerate oral medications and has a normal gastrointestinal transit time. CSP is given until day 100, and may taper on day 101 if there is no graft versus host disease. Patients also receive MMF IV every 8 hours on days 0 to 7 and then may receive MMF PO beginning day 8 to 30. MMF is continued for a minimum of 30 days or until 7 days after blood counts recover whichever is later. If there is no evidence of acute GVHD and donor CD3 engraftment is at least 50% from one donor MMF may be tapered.
PURPOSE:To produce the titled composition having improved peroral absorptivity, by adding a sucrose fatty acid ester to a beta-lactam antibiotic having excellent antibacterial activity and antibacterial spectrum but only poor peroral absorptivity. CONSTITUTION:The objective beta-lactam agent composition for oral administration is obtained by compounding 1pt.wt. of a beta-lactam antibiotic (e.g. cephalosporin compound, penicillin compound, etc.) with 0.01-50pts.wt. of a sucrose fatty acid ester. Although beta-lactam antibiotics have excellent safety, antibacterial activity and antibacterial spectrum and are used most frequently among the antibiotics, however, the beta-lactam antibiotics are administered in the form of injection with little exception, and the peroral drug thereof has lower antibacterial activity than injection, etc. The addition of the sucrose fatty acid ester improves the peroral absorptivity, and gives a beta-lactam agent having excellent antibacterial activity.
The in-clinic arm of this study will deliver half of the rehabilitation treatment sessions at a study site providing traditional outpatient therapy, continuously supervised by a licensed therapist. The unsupervised therapy sessions will take place in the patient's home, and will be guided by an individualized booklet generated and printed by the Treatment Therapist and distributed to the subject during the first in-clinic therapy visit. The content of the unsupervised therapy sessions will be matched to the same exercise and training components provided during the subject's in-clinic supervised therapy sessions. In addition, at the start of each of the unsupervised sessions, all subjects will receive 5 minutes of stroke education.
PROBLEM TO BE SOLVED: To provide a new protein having respectively specific molecular weight, isoelectric point and partial amino acid sequence, inducing the formation of interferon-γ in an immunopathologically mediated tissue and useful e.g. as a treating and preventing agent for viral diseases, malignant tumor, immunologic diseases, etc. SOLUTION: The objective protein is a new protein having a molecular weight of 19,000±5,000 Dalton measured by SDS polyacrylamide gel electrophoresis or gel-filtration method and an isoelectric point of 4.8±1.0 measured by chromatofocusing method and exhibiting a biological action to induce the formation of interferon-γ in an immunopathologically mediated tissue or a protein immunologically equivalent to the above protein. The protein is useful e.g. as a treating agent or preventing agent for viral diseases, malignant tumor and immunologic diseases in general. The protein can be produced by preparing a cDNA library using an mRNA collected from mouse liver cell, searching the library with a probe, inserting the obtained gene into a vector and expressing the product.
This clinical practice guideline from the American Society for Gastrointestinal Endoscopy (ASGE) provides an evidence-based approach for the role of endoscopy in the management of chronic pancreatitis (CP). This document was developed using the Grading of Recommendations Assessment, Development and Evaluation framework. The guideline addresses effectiveness of endoscopic therapies for the management of pain in CP, including celiac plexus block, endoscopic management of pancreatic duct (PD) stones and strictures, and adverse events such as benign biliary strictures (BBSs) and pseudocysts. In patients with painful CP and an obstructed PD, the ASGE suggests surgical evaluation in patients without contraindication to surgery before initiation of endoscopic management. In patients who have contraindications to surgery or who prefer a less-invasive approach, the ASGE suggests an endoscopic approach as the initial treatment over surgery, if complete ductal clearance is likely. When a decision is made to proceed with a celiac plexus block, the ASGE suggests an EUS-guided approach over a percutaneous approach. The ASGE suggests indications for when to consider ERCP alone or with pancreatoscopy and extracorporeal shock wave lithotripsy alone or followed by ERCP for treating obstructing PD stones based on size, location, and radiopacity. For the initial management of PD strictures, the ASGE suggests using a single plastic stent of the largest caliber that is feasible. For symptomatic BBSs caused by CP, the ASGE suggests the use of covered metal stents over multiple plastic stents. For symptomatic pseudocysts, the ASGE suggests endoscopic therapy over surgery. This document clearly outlines the process, analyses, and decision processes used to reach the final recommendations and represents the official ASGE recommendations on the above topics.
Uncontrolled secretion of ECM proteins, such as collagen, can lead to excessive scarring and fibrosis and compromise tissue function. Despite the widespread occurrence of fibrotic diseases and scarring, effective therapies are lacking. A promising approach would be to limit the amount of collagen released from hyperactive fibroblasts. We have designed membrane permeant peptide inhibitors that specifically target the primary interface between TANGO1 and cTAGE5, an interaction that is required for collagen export from endoplasmic reticulum exit sites (ERES). Application of the peptide inhibitors leads to reduced TANGO1 and cTAGE5 protein levels and a corresponding inhibition in the secretion of several ECM components, including collagens. Peptide inhibitor treatment in zebrafish results in altered tissue architecture and reduced granulation tissue formation during cutaneous wound healing. The inhibitors reduce secretion of several ECM proteins, including collagens, fibrillin and fibronectin in human dermal fibroblasts and in cells obtained from patients with a generalized fibrotic disease (scleroderma). Taken together, targeted interference of the TANGO1-cTAGE5 binding interface could enable therapeutic modulation of ERES function in ECM hypersecretion, during wound healing and fibrotic processes.
BACKGROUND AND PURPOSE: IL-11 is a member of the IL-6 family of cytokine initially considered as haematopoietic and cytoprotective factor. Recent evidence indicates that IL-11 promotes lung fibrosis and pulmonary hypertension in animal models and is elevated in lung tissue of patients with pulmonary fibrosis and pulmonary hypertension. Fibrocytes are bone marrow-derived circulating cells that participate in lung fibrosis and pulmonary hypertension, but the role of IL-11 on fibrocytes is unknown. We investigated the role of IL-11 system on fibrocyte activation in different in vitro and in vivo models of lung fibrosis associated with pulmonary hypertension.
EXPERIMENTAL APPROACH: Human fibrocytes were isolated from peripheral blood of six healthy donors. Recombinant human (rh)-IL-11 and soluble rh-IL-11 receptor, α subunit (IL-11Rα) were used to stimulated fibrocytes in vitro to measure:- cell migration in a chemotactic migration chamber, fibrocyte to endothelial cell adhesion in a microscope-flow chamber and fibrocyte to myofibroblast transition. Mouse lung fibrosis and pulmonary hypertension was induced using either IL-11 (s.c.) or bleomycin (intra-tracheal), while in the rat monocrotaline (intra-tracheal) was used. In vivo siRNA-IL-11 was administered to suppress IL-11 in vivo.
KEY RESULTS: RhIL-11 and soluble rhIL-11Rα promote fibrocyte migration, endothelial cell adhesion and myofibroblast transition. Subcutaneous (s.c.) IL-11 infusion elevates blood, bronchoalveolar and lung tissue fibrocytes. SiRNA-IL-11 transfection in bleomycin and monocrotaline animal models reduces blood and lung tissue fibrocytes and reduces serum CXCL12 and CXCL12/CXCR4 lung expression.
CONCLUSION AND IMPLICATIONS: Targeting IL-11 reduces fibrocyte circulation and lung accumulation in animal models of pulmonary hypertension-associated lung fibrosis.
PURPOSE: To develop a convolutional neural network (CNN) model to diagnose skull-base invasion by nasopharyngeal malignancies in CT images and evaluate the model's diagnostic performance.
MATERIALS AND METHODS: We divided 100 malignant nasopharyngeal tumor lesions into a training (n = 70) and a test (n = 30) dataset. Two head/neck radiologists reviewed CT and MRI images and determined the positive/negative skull-base invasion status of each case (training dataset: 29 invasion-positive and 41 invasion-negative; test dataset: 13 invasion-positive and 17 invasion-negative). Preprocessing involved extracting continuous slices of the nasopharynx and clivus. The preprocessed training dataset was used for transfer learning with Residual Neural Networks 50 to create a diagnostic CNN model, which was then tested on the preprocessed test dataset to determine the invasion status and model performance. Original CT images from the test dataset were reviewed by a radiologist with extensive head/neck imaging experience (senior reader: SR) and another less-experienced radiologist (junior reader: JR). Gradient-weighted class activation maps (Grad-CAMs) were created to visualize the explainability of the invasion status classification.
RESULTS: The CNN model's diagnostic accuracy was 0.973, significantly higher than those of the two radiologists (SR: 0.838; JR: 0.595). Receiver operating characteristic curve analysis gave an area under the curve of 0.953 for the CNN model (versus 0.832 and 0.617 for SR and JR; both p < 0.05). The Grad-CAMs suggested that the invasion-negative cases were present predominantly in bone marrow, while the invasion-positive cases exhibited osteosclerosis and nasopharyngeal masses.
CONCLUSIONS: This CNN technique would be useful for CT-based diagnosis of skull-base invasion by nasopharyngeal malignancies.
CAET was based on a combination of aerobic, resistance, balance, and flexibility exercises. The exercise on the cycle ergometer started with 5-min of warm-up followed by 3 bouts of continuous cycling at a steady-state intensity. The duration of the bouts (5-10 min) and the intensity (55-85% HRR) were progressively increased throughout each phase. To ensure that the participants exercised at the appropriate intensity, the OMNI scale 4-6 (Stanish \& Aucoin, 2007) was used during the home-based intervention, and an HR chest band (H10 Polar, Electro, Kempele, Finland) was worn during the gym-based intervention.
Subjects in the control group will continue care as usual with their diabetes team, without supplementation of the bant application. Participants will have their A1C levels measured every 3 months (for 1 year), as well as complete questionnaires/interviews relating to their diabetes management and lifestyle.